| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 13,069.0 | 12,222.0 |
| Profit before tax | 2,536.0 | 3,114.0 |
| Net income | 2,162.0 | 2,201.0 |
| EPS (diluted, $ a share) | $1.05 | $1.08 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -1.8% |
|---|---|
| Revenue, year on year | +6.9% |
10-Q filed with the SEC, NYSE: BMY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Bristol Myers Squibb Co: key numbers
- Share price
- $62.93Close, Nov 16
- Market cap
- $129B
- Shares outstanding
- 2.04BLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bristol Myers Squibb Co
All →Bristol Myers Squibb Insider Julia A. Haller Sells $241K of Stock
Julia A. Haller sold 3,800 shares of Bristol Myers Squibb Co at $63.31 a share, worth $241K in total on Nov 5, 2026. Shares held after the trade: 30,279 (-11.2%).
- Value
- $241K
- Shares
- 3,800
- Price
- $63.31
- Holding change
- -11.2%
- Trade date
- Nov 5, 2026
Bristol Myers Squibb Financial Results
Bristol Myers Squibb reported third quarter 2026 revenues of $13.1 billion, a 7% increase driven by double-digit growth in its Growth Portfolio. The company raised its full-year 2026 revenue guidance to a range of $49.75 billion to $50.25 billion following strong performance from key products like Opdivo Qvantig and Reblozyl.
- Term
- Q3 2026
“We delivered another quarter of double-digit growth in our Growth Portfolio, which increased 12% and reflects the continued momentum across our diversified portfolio. The approval of Zenbexus, the first-in-class CELMoD, brings a new class of treatment to market for patients with multiple myeloma and is one of several recent pipeline milestones. As we look forward to additional late-stage data in the near term, we remain focused on executing with discipline, investing where we see the greatest opportunity and strengthening the foundation for sustainable growth.”
Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb